HER2-positive tumours display intermediate immune infiltration and may derive benefit from checkpoint blockade particularly when combined with HER2-targeted agents, while luminal (ER+/PR+) tumours generally exhibit lower baseline immunogenicity and variable PD-L1 expression, often associated with poorer responses to monotherapy checkpoint inhibition [23]. The gene discussed is PGR; the disease is neoplasm.